228 related articles for article (PubMed ID: 23238015)
1. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.
Britschgi A; Andraos R; Brinkhaus H; Klebba I; Romanet V; Müller U; Murakami M; Radimerski T; Bentires-Alj M
Cancer Cell; 2012 Dec; 22(6):796-811. PubMed ID: 23238015
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
[TBL] [Abstract][Full Text] [Related]
3. JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition.
Yeh JE; Toniolo PA; Frank DA
JAKSTAT; 2013 Oct; 2(4):e24635. PubMed ID: 24470973
[TBL] [Abstract][Full Text] [Related]
4. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
6. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer.
Kim MS; Lee WS; Jeong J; Kim SJ; Jin W
Oncotarget; 2015 Nov; 6(37):40158-71. PubMed ID: 26515594
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
Riggio M; Polo ML; Blaustein M; Colman-Lerner A; Lüthy I; Lanari C; Novaro V
Carcinogenesis; 2012 Mar; 33(3):509-18. PubMed ID: 22180571
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
9. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
10. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
[TBL] [Abstract][Full Text] [Related]
11. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
12. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
[TBL] [Abstract][Full Text] [Related]
14. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
16. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
Kolev VN; Wright QG; Vidal CM; Ring JE; Shapiro IM; Ricono J; Weaver DT; Padval MV; Pachter JA; Xu Q
Cancer Res; 2015 Jan; 75(2):446-55. PubMed ID: 25432176
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line.
Guvenir Celik E; Eroglu O
Mol Biol Rep; 2023 Jan; 50(1):319-329. PubMed ID: 36331743
[TBL] [Abstract][Full Text] [Related]
18. Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?
Britschgi A; Radimerski T; Bentires-Alj M
Drug Resist Updat; 2013; 16(3-5):68-72. PubMed ID: 24169539
[TBL] [Abstract][Full Text] [Related]
19. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.
Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA; Santoro M
Clin Cancer Res; 2012 Jul; 18(13):3532-40. PubMed ID: 22753663
[TBL] [Abstract][Full Text] [Related]
20. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Chang KY; Tsai SY; Wu CM; Yen CJ; Chuang BF; Chang JY
Clin Cancer Res; 2011 Nov; 17(22):7116-26. PubMed ID: 21976531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
